Guiding fluid removal in critically ill patients using bioelectrical impedance analysis
Optimization of Fluid Balance Guided by Bioelectrical Impedance Analysis in Patients Undergoing Continuous Renal Replacement Therapy in Critical Care
This study tests if using a special tool to measure body water can help doctors better manage fluid removal in critically ill patients on kidney treatment, to see if it improves their health outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Salouël) |
| Trial ID | NCT06799910 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates the effectiveness of using bioelectrical impedance analysis (BIA) to guide fluid removal in critically ill patients undergoing continuous renal replacement therapy (CRRT). It compares two groups: one receiving standard fluid removal prescriptions based on clinical judgment and another guided by the extracellular to total body water ratio measured by BIA. The goal is to determine if this BIA-guided approach leads to better fluid balance and outcomes over a 72-hour period. The study is conducted at a single center, the Amiens-Picardie University Hospital.
Who should consider this trial
Good fit: Ideal candidates are critically ill patients over 18 years old with significant fluid overload receiving continuous veno-venous hemofiltration.
Not a fit: Patients with invalid BIA measurements or those with chronic dialysis or severe cardiac conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved fluid management and reduced complications in critically ill patients requiring renal replacement therapy.
How similar studies have performed: While this approach is innovative, similar studies using bioelectrical impedance for fluid management in other settings have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * The patient was hospitalized in the intensive care unit of Amiens-Picardie University Hospital. * Patient with an increase in fluid balance (TBW \> 5%) * Patient receiving continuous veno-venous hemofiltration (CVVH) on a PrismaFlexR or PrisMaxR machine, initiated due to oliguria, potassium level \> 6.5 mmol/L, urea level \> 25 mmol/L, or creatinine \> 300 µmol/L and severe metabolic acidosis (pH \< 7.2). * Hemodynamically stable patient with a mean arterial pressure (MAP) \> 65 mmHg for more than 4 hours with norepinephrine. * Signed consent to participate in the study by the patient or, if unconscious, their legal representative/next of kin. Exclusion Criteria: * Invalid BIA measurements * Internal device powered by an electrical current (pacemaker, implantable cardioverter-defibrillator, neurostimulator) * Cardiac arrhythmia (atrial fibrillation, atrial flutter) present at the inclusion * Chronic dialysis patient * Moribund patient * The patient is on extracorporeal mechanical support * Hemorrhagic shock * Pregnant woman * Patient under guardianship or conservators.
Where this trial is running
Salouël
- CHRU Amiens — Salouël, France (Recruiting)
Study contacts
- Study coordinator: Christophe Beyls, MD
- Email: beyls.christophe@chu-amiens.fr
- Phone: 33 + 03 22 08 78 66
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.